UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease

Hepatology (Baltimore, Md.), 2022-08, Vol.76 (2), p.469-482

2022

Volltextzugriff (PDF)

An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory‐Wide Study From 2000 to 2017

Hepatology (Baltimore, Md.), 2020-02, Vol.71 (2), p.444-455

2020

Volltextzugriff (PDF)

Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID‐19

Hepatology (Baltimore, Md.), 2021-10, Vol.74 (4), p.1750-1765

2021

Volltextzugriff (PDF)

Liver stiffness measurement predicts long‐term survival and complications in non‐alcoholic fatty liver disease

Liver international, 2020-03, Vol.40 (3), p.581-589

2020

Volltextzugriff (PDF)

Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis

Alimentary pharmacology & therapeutics, 2019-11, Vol.50 (9), p.1037-1048

2019

Volltextzugriff (PDF)

Risk of severe infection in patients with non‐alcoholic fatty liver disease: Implication on clinical management

Liver international, 2023-10, Vol.43 (10), p.2057-2059

2023

Volltextzugriff (PDF)

Risk of liver‐related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease

Hepatology (Baltimore, Md.), 2022-11, Vol.76 (5), p.1409-1422

2022

Volltextzugriff (PDF)

Editorial: Can liver fat quantification stratify cardiovascular risk in type 2 diabetes?

Alimentary pharmacology & therapeutics, 2023-11, Vol.58 (10), p.1107-1108

2023

Volltextzugriff (PDF)

Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti‐viral therapy

Alimentary pharmacology & therapeutics, 2021-09, Vol.54 (5), p.722-723

2021

Volltextzugriff (PDF)

Editorial: improvement of cardiovascular risk factor control in patients with type 2 diabetes and nonalcoholic fatty liver disease—time for action! Authors' reply

Alimentary pharmacology & therapeutics, 2023-05, Vol.57 (10), p.1172-1173

2023

Volltextzugriff (PDF)

Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment

Alimentary pharmacology & therapeutics, 2018-11, Vol.48 (9), p.984-992

2018

Volltextzugriff (PDF)

Letter: vaccination for global control of hepatitis B—from prevention to elimination. Authorsʼ reply

Alimentary pharmacology & therapeutics, 2022-12, Vol.56 (11-12), p.1629-1630

2022

Volltextzugriff (PDF)

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance

Alimentary pharmacology & therapeutics, 2024-05, Vol.59 (10), p.1223-1235

2024

Volltextzugriff (PDF)

MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease

Alimentary pharmacology & therapeutics, 2023-12, Vol.58 (11-12), p.1194-1204

2023

Volltextzugriff (PDF)

Letter: systematic review with meta‐analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B

Alimentary pharmacology & therapeutics, 2022-03, Vol.55 (5), p.616-617

2022

Volltextzugriff (PDF)

Risk and predictors of hepatic decompensation in grey zone patients by the Baveno VII criteria: A competing risk analysis

Alimentary pharmacology & therapeutics, 2023-11, Vol.58 (9), p.920-928

2023

Volltextzugriff (PDF)

Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue‐induced hepatitis B surface antigen loss

Alimentary pharmacology & therapeutics, 2021-01, Vol.53 (2), p.321-331

2021

Volltextzugriff (PDF)

Machine learning model to predict recurrent ulcer bleeding in patients with history of idiopathic gastroduodenal ulcer bleeding

Alimentary pharmacology & therapeutics, 2019-04, Vol.49 (7), p.912-918

2019

Volltextzugriff (PDF)

Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort

Liver international, 2024-05, Vol.44 (5), p.1129-1141

2024

Volltextzugriff (PDF)

HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough

Journal of gastroenterology and hepatology, 2020-10, Vol.35 (10), p.1661-1662

2020

Volltextzugriff (PDF)

Incidence of hepatocellular carcinoma and mortality in chronic viral hepatitis in an Asian population with and without HIV infection

Alimentary pharmacology & therapeutics, 2023-10, Vol.58 (8), p.814-823

2023

Volltextzugriff (PDF)

Machine‐learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD‐related liver fibrosis

Liver international, 2024-03, Vol.44 (3), p.749-759

2024

Volltextzugriff (PDF)

Biochemical follow‐up of nonfunctioning benign thyroid nodules

Clinical endocrinology (Oxford), 2021-02, Vol.94 (2), p.322-329

2021

Volltextzugriff (PDF)

Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages

Journal of gastroenterology and hepatology, 2023-08, Vol.38 (8), p.1381-1388

2023

Volltextzugriff (PDF)

Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study

Alimentary pharmacology & therapeutics, 2023-05, Vol.57 (10), p.1103-1116

2023

Volltextzugriff (PDF)

1 – 25 von 254

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(240)
Mit Volltextzugriff
(221)

Publikationsform

Artikel
(252)
Tagungsberichte
(2)

Sprache

Englisch
(250)
Koreanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease

An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory‐Wide Study From 2000 to 2017

Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID‐19

Liver stiffness measurement predicts long‐term survival and complications in non‐alcoholic fatty liver disease

Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis

Risk of severe infection in patients with non‐alcoholic fatty liver disease: Implication on clinical management

Risk of liver‐related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease

Editorial: Can liver fat quantification stratify cardiovascular risk in type 2 diabetes?

Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti‐viral therapy

Editorial: improvement of cardiovascular risk factor control in patients with type 2 diabetes and nonalcoholic fatty liver disease—time for action! Authors' reply

Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment

Letter: vaccination for global control of hepatitis B—from prevention to elimination. Authorsʼ reply

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance

MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease

Letter: systematic review with meta‐analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B

Risk and predictors of hepatic decompensation in grey zone patients by the Baveno VII criteria: A competing risk analysis

Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue‐induced hepatitis B surface antigen loss

Machine learning model to predict recurrent ulcer bleeding in patients with history of idiopathic gastroduodenal ulcer bleeding

Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort

HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough

Incidence of hepatocellular carcinoma and mortality in chronic viral hepatitis in an Asian population with and without HIV infection

Machine‐learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD‐related liver fibrosis

Biochemical follow‐up of nonfunctioning benign thyroid nodules

Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages

Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study

Suchergebnisse filtern